Lonza to Establish Biomanufacturing Base in China
December 10 2018 - 3:59AM
Dow Jones News
By Nathan Allen
Swiss pharmaceutical company Lonza Group AG (LONN.EB) said
Monday that it has signed an agreement to set up a manufacturing
plant for biological products in China's Guangzhou province using
technology provided by GE Healthcare.
The facility will be based on GE Healthcare's off-the-shelf
KUBio manufacturing platform and should come online by 2020, Lonza
said.
The plant forms part of a larger biomanufacturing initiative
between GE Healthcare and Guangzhou Development District, Lonza
said.
Write to Nathan Allen at nathan.allen@dowjones.com
(END) Dow Jones Newswires
December 10, 2018 03:44 ET (08:44 GMT)
Copyright (c) 2018 Dow Jones & Company, Inc.
GE Aerospace (NYSE:GE)
Historical Stock Chart
From Aug 2024 to Sep 2024
GE Aerospace (NYSE:GE)
Historical Stock Chart
From Sep 2023 to Sep 2024